Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K Wenn,L Tomala,Stefan Wilop,Lucia Vankann,C Hasenbank,O Frank,Andreas Hochhaus,F. Giles,Thoralf Lange,Martin C. Müller,Steffen Koschmieder,Fabian Beier,Patrick Ziegler,Tim H. Brümmendorf

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

2015

K Wenn
L Tomala
Stefan Wilop
Lucia Vankann
C Hasenbank
O Frank
Andreas Hochhaus
F. Giles
Thoralf Lange
Martin C. Müller
Steffen Koschmieder
Fabian Beier
Patrick Ziegler
Tim H. Brümmendorf

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

Keywords:

Cancer research
Genetics
Molecular Response
Nilotinib
Telomere
Biology
Chronic phase chronic myeloid leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations